Compare Humana Inc (HUM) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Newmont Corporation — how do they compare? Humana Inc trades at $403.99 (market cap $47.81B), while Newmont Corporation trades at $91.58 (market cap $95.23B). The key difference: Newmont Corporation is the larger of the two by market cap, and Newmont Corporation pays the higher dividend (1.17%). Which is the better fit depends on your goals.
| HUM | NEM | |
|---|---|---|
Market Cap | $47.81B | $95.23B |
Sector | Health | Basic Materials |
52-Week High | $409.42 | $131.95 |
52-Week Low | $163.67 | $59.86 |
Enterprise Value | $56.85B | $91.98B |
Dividend Yield | 0.89% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
Newmont Corporation (NEM) trades at $89.52, down 0.2% over 24 hours, with technical indicators showing a bearish trend. The company reported strong fundamentals with Q1 2026 EPS of $2.90 beating expectations of $2.07, revenue growth to $22.67 billion in 2025, and robust cash flow from operations of $10.33 billion. Analyst sentiment remains overwhelmingly positive with 28 buy ratings and a consensus price target of $139.22, suggesting significant upside potential from current levels.
The outlook for Newmont is favorable due to strong earnings momentum, attractive valuation multiples (P/E of 11.63), and projected revenue growth to $25.0 billion in 2026. Key risks include exposure to gold price volatility, rising unit costs pressuring margins, and execution challenges in production growth. The stock presents a compelling opportunity for value-oriented investors given the disconnect between current price and analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
